Argenx announces publication of phase 3 adapt trial results of efgartigimod for the treatment of generalized myasthenia gravis in the lancet neurology

Results from adapt showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gmg )

ARGX Ratings Summary

ARGX Quant Ranking